Phase 1 study of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Latest Information Update: 23 Apr 2018
At a glance
- Drugs Nalmefene (Primary) ; Nalmefene
- Indications Opioid-related disorders
- Focus Pharmacokinetics
- 18 Apr 2018 According to Opiant Pharmaceuticals media release, the company has been awarded a grant of approximately $7.4 million from the National Institutes of Healths National Institute on Drug Abuse (NIDA) for the development of OPNT003 (intranasal nalmefene), the grant follows encouraging data from this study.
- 20 Feb 2018 New trial record
- 12 Feb 2018 According to Opiant Pharmaceuticals media release, company announced results. and provided an update on a meeting held February 8, 2018 with the U.S. Food and Drug Administration (FDA) regarding its planned development program.